I N T R O D U C T I O N
Sudden cardiac arrest is the most common cause of death for end-stage renal disease patients treated with haemodialysis, occurring at a rate 30 times greater than in the general population. Part of the adverse influence of haemodialysis [1] likely results from the non-physiological nature of rapid fluid and electrolyte shifts that occur during a thrice-weekly haemodialysis schedule [2] .
Several observational studies have reported increased mortality rates in chronic haemodialysis patients presenting hyperkalaemia (HK) [3] [4] [5] [6] [7] [8] or hypokalaemia [4, 5] . Similar trends have also been observed when considering sudden cardiac arrest [2] . In chronic haemodialysis patients, serum potassium may vary erratically from one moment to the next, due to a number of factors: fluctuation in dietary intake of potassium, volume of residual diuresis, level of gastrointestinal loss (diarrhoea), changes in blood glucose and insulin, intensity of metabolic acidosis, frequency and duration of haemodialysis sessions, potassium and bicarbonate concentrations of the dialysis bath, renin angiotensin system inhibitors and/or loop diuretic doses, and, in some countries, the use of potassiumbinding agents [9] . The Dialysis Outcomes and Practice Patterns Study (DOPPS) 2002-11 data showed that France is the country where potassium-binding agents are the more frequently prescribed. Indeed, in Belgium, Canada, Italy and Sweden (nations where 5% of patients were prescribed a sodium-based potassium-binding resin, while seven other countries had <5% use), 20% of patients were prescribed a potassium-binding resin overall versus 40-50% of patients in France [9] . These agents were found to be associated with greater interdialytic weight gain as well as higher serum bicarbonate, phosphorus and sodium concentrations, although without increased mortality [9] . Other mitigation strategies towards HK may include, beyond diet recommendations, the use of low-potassium concentration (i.e. <3 mmol/L) dialysis baths, with dramatic differences across countries according to the DOPPS data, although such strategies were found to be associated with increased death rates in the latter study [10] . Low-potassium dialysates of <2 mEq/L have also been found to be associated with increased haemodialysis-associated sudden cardiac arrest rates in a case-control study [2] .
In the present study, we aimed to assess the contemporary prevalence and recurrence of HK along with the concomitant use of low-potassium concentration dialysis baths and the prescription of potassium-binding agents in a French regional disease management programme-associated registry, that is, in the country most prone to use such agents.
M A T E R I A L S A N D M E T H O D S
This is a prospective (2 January 2014 to 31 December 2015), multicentre (14 chronic haemodialysis centres, Lorraine Region, France) study in a regional disease management programme setting ['Association Lorraine de Traitement de l'Insuffisance Rénale Chronique (ALTIR)'], which maintains a registry as an electronic health record (EHR). All routine chemistry determinations prescribed in patients are automatically entered in the registry. As per French health authority requirements, serum potassium should be routinely measured before the midweek session: this was actually the case for 96% of the study population. Only predialysis serum potassium concentrations are considered in the present analysis (14 734 measurements). The population consisted of 527 ALTIR chronic haemodialysis patients followed during the study period. The usual dialysis regimen encompasses three dialysis sessions per week, of 4 h each, which may be further extended in the event of an excessive interdialytic weight gain, without exceeding a 700 mL/h ultrafiltration rate, with also the potential use of an additional dialysis session when deemed necessary, based on the judgment of the treating physician. In addition to medical examinations, individual interviews with a dietician (qualitative assessments) are performed at regular intervals. The use of anonymized data for research purposes was performed under the Commission Nationale Informatique et Libertés (CNIL) agreement no. 576063, 1998.
Statistical analysis
Expanded methods are provided in the Supplementary data. All analyses were performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
HK was defined as follows: the value of serum potassium exceeding a pre-specified threshold at any time during the study period (2 years) according to three different thresholds (potassium >5.1 mmol/L, 5.5 mmol/L or 6 mmol/L).
Hypokalaemia was defined according to three different thresholds (potassium <4 mmol/L, 3.5 mmol/L or 3 mmol/L).
Recurrence or persistence of HK (potassium >5.1 mmol/L, 5.5 mmol/L or 6 mmol/L) within a period of the first month, the first 2 months or the first 3 months following diagnosis of HK was defined as the presence of HK according to the same threshold (potassium >5.1 mmol/L, 5.5 mmol/L or 6 mmol/L) within the considered period.
Normokalaemia (4.0-5.0 mmol/L) was defined as the stability of the serum potassium value during the considered period; all values of potassium should remain within this range.
Patient characteristics at baseline were collected in the entire study population in which demographic, dialysis and medication intake data are presented. For this purpose, continuous variables are expressed as mean 6 standard deviation (SD), minimum, maximum and median (interquartile range), while categorical variables are expressed as frequencies (percentages).
R E S U L T S HK at baseline and during the 2-year period
Patient baseline features are presented in Table 1 . The median number of serum potassium measurements was 24 (interquartile range 8-44). The average serum potassium at baseline was in the normal range (4.8 6 0.7 mmol/L) while 26.4%, 13.8% and 4.9% of the patients were hyperkalaemic (as defined by a serum potassium >5.1, 5.5 or 6 mmol/L, respectively) and 12.5%, 1.9% and 0.4% of the patients were hypokalaemic (as defined by a serum potassium <4, 3.5 or 3 mmol/L, respectively). At baseline, 61% of the patients were being prescribed a potassium-binding resin [essentially sodium polystyrene sulfonate (SPS), prescribed on a daily basis in 52% of cases], with 2 and 3 mmol/L potassium concentration dialysis baths being used in relatively equal proportions (50.9% versus 47.7%). Thereafter, the proportion of patients being prescribed any potassium-binding agent increased up to 78%.
The overall percentage of patients experiencing HK anytime during follow-up was 73.8% (389/527 for serum potassium >5.1 mmol/L), 57.9% (305/527 for serum potassium >5.5 mmol/L) and 34.5% (182/527 for serum potassium >6 mmol/L).
Significant seasonal trends were only observed in instances of serum potassium >6 mmol/L, with the highest rates observed in summer. Of note, higher HK rates >5.1 and 5.5 mmol/L were also observed in summer (Figure 1) .
The factors associated with HK occurrence in univariate and multivariate analyses are presented as Supplementary data, Tables S1, S2 and S3. Among the variables tested, a higher prescription rate of potassium binders was the only factor Table 1 . Baseline patient characteristics and use of potassium-binding agents at baseline and throughout the following 2 years Figure 2 . Results reveal that 2 and 3 mmol/L potassium baths remained equally used, with a stepwise increase in potassium-binding resin prescription as a function of HK severity. Table 2 , a high rate of HK recurrence was observed 1, 2 and 3 months after an HK occurrence (e.g. 35.6% of HKs >6 mmol/L within 3 months after an initial HK of the same magnitude).
Recurrence of HK

As illustrated in
When considering the evolution of serum potassium after an initial HK occurrence (as defined by serum potassium >5.5 mmol/L herein), only 6.3% of the patients displayed normokalaemia during the next 3 months, whereas 59.7% experienced an HK of the same magnitude, while 80% experienced an HK >5.1 mmol/L and 24.0% a hypokalaemia <4 mmol/L ( Table 3) .
The Supplementary data Tables S4 and S5 depict the patterns of potassium bath concentrations and potassium-binding agent prescription rates during the 3-month period following an HK episode. With regard to potassium bath concentrations, a relative stability was observed within 3 months after an HK >5.1 or 5.5 mmol/L. However, in case of a recurrent HK >6 mmol/L, the use of 2 mmol/L potassium baths increased from 50.8% initially to 54% after 1-2 months, reaching 59.3% after 3 months. Of note, a 1 mmol/L potassium bath was still exceptionally prescribed (<3%) in this setting. As a function of the magnitude of the initial HK, a stepwise increase in the prescription rate of potassium binders was observed (66.1%, 73% and 83.7% for HK >5.1, 5.5 and 6 mmol/L, respectively). Irrespective of the initial HK threshold considered, the prescription rate of SPS increased over time in patients with persistent HK.
Moreover, in patients with an initial HK >5.5 or 6 mmol/L, this was accompanied by an increased proportion of patients being prescribed SPS daily as opposed to every other day (from 51.5% to 56% for HK >5.5 mmol/L; from 54.3% to 63% for HK >6 mmol/L).
D I S C U S S I O N
These up-to-date registry data clearly demonstrate the heavy burden of HK in this French regional management programme of chronic haemodialysis, despite proactive mitigation strategies including a dynamic management of the prescription of lower potassium baths and potassium binders. To the best of our knowledge, this is the first report of both HK prevalence and the rates of its recurrence after a hyperkalaemic episode. All were found to be dramatically elevated. For instance, the overall percentage of patients experiencing HK anytime during the 2-year follow-up was 73.8% for serum potassium >5.1 mmol/L, 57.9% for serum potassium >5.5 mmol/L and 34.5% for serum potassium >6 mmol/L. In contrast, in a retrospective study, HK >5 mmol/L was reported as being present in 'only' 39% of routine laboratory results from US large dialysis providers during the 2001-04 period [5] . In this latter survey, the majority (63%) of patients underwent maintenance haemodialysis against a dialysate potassium bath in the 1.1-2.0 mEq/L range, including the 2.0 mEq/L potassium bath, the latter being the dominant prescription in most patients. Of note, the very infrequent use of potassium resins in some countries, including the USA, likely results, at least partly, from concerns related to the risk of colonic necrosis under Kayexalate mixed with 70% sorbitol, the hitherto usual preparation in the USA [9, 11] . Furthermore, in patients with volume overload, the use of SPS may be associated with volume expansion [9, 12, 13] and the development of manifest heart failure since SPS exchanges potassium for sodium [14] .
In the present study, despite a high usage rate (approximately 50%) of low-potassium dialysis bath concentrations (<3 mmol/L) [as opposed to 1 mmol/L baths being Among the 278 patients having SPS prescribed at baseline, only 5 (1.8%) patients were prescribed SPS during the long interdialytic interval only and were counted within the 'every other day' category.
b Overall, 5/11 patients were included in the ALCHEMIST trial ClinicalTrials.gov identifier: NCT01848639: after a 1-month run-in period under 25 mg every other day of spironolactone administered per os after dialysis sessions three times a week, patients are randomized to spironolactone or placebo. The dose should be increased to 25 mg once daily and is adjustable using an algorithm. CRP, C reactive protein. K, potassium. , along with a very high concomitant prescription rate of potassium-chelating agents (mostly SPS, being prescribed either every other day or daily, that is, even during dialysis days), a very high rate of HK and of recurrent HK was nonetheless observed. These alarming data clearly demonstrate the failure of current mitigation strategies to maintain predialytic serum potassium in a 'safe' normal range. In our registry, increased HK rates were observed in summer, hence in contrast to observations in the USA where winter was associated with higher serum potassium levels [15, 16] . Such discrepancies may be associated with different dietary patterns across countries. Adherence to a potassium restriction diet is obviously of importance since a higher dietary potassium intake was found to be significantly, albeit modestly, associated (R ¼ 0.14, P < 0.05, n ¼ 224 dialysis patients in the USA) with increased predialytic potassium concentrations [17] . Qualitative dietary assessments are routinely performed in our institution; whether repeated quantitative dietary assessments may improve patient adherence to the potassium restriction diet and serum potassium control may be worth testing. Adherence to the prescribed potassium-binding agents is also highly questionable herein, owing to the known poor gut tolerability of both SPS and calcium polystyrene sulfonate (CPS). Whether the US Food and Drug Administration (FDA)-approved calcium-potassium-exchanger patiromer may enable the possibility of minimizing potassium fluctuations and provide safer dialysis deserves further study. Studies using patiromer in conjunction with a more physiological potassium dialysate are also needed to determine whether arrhythmic events, both during and postdialysis, can be decreased using such an approach. Of interest, in a phase 2 metabolic study performed early in the clinical development programme of patiromer, the daily administration of the potassium binder patiromer (12.6 g/day, which is half the FDA-approved maximum dosage) reduced both serum potassium and serum phosphate in six hyperkalaemic haemodialysis patients. Patiromer treatment also significantly decreased the proportion of days patients were hyperkalaemic compared with the pretreatment week. There were no patient discontinuations due to treatment intolerance and no serious adverse events [18] .
Limitations
This is a regional survey, thus the generalizability of these results are uncertain. Its sample size and its short-term duration precluded us from reliably assessing the association between potassium/low-potassium concentration baths/potassium binders and outcomes, and is thus beyond the scope of this report. Its strengths include the registry perspective (i.e. completeness of the biological data, which were automatically chronicled, along with the systematic availability of potassium bath and potassium binder prescriptions within an EHR).
Conclusion
A very high prevalence and recurrence of HK was observed in this contemporary registry, despite the widespread simultaneous prescription and dynamic management of low-potassium dialysis bath concentrations and of potassium binders. Developing safe therapies that improve cardiovascular outcomes for haemodialysis patients is a high priority. Owing to the well-known association of dyskalaemia and death in chronic haemodialysis patients and the quick availability of new therapeutic options (i.e. new potassium binders), our results underscore the urgent need to design dedicated randomized trials aimed at assessing the optimal mitigating strategies to avoid dyskalaemia and improve patient outcomes.
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